Oxigene

In 2010, OXiGENE acquired VaxGen, Inc. in a stock-for-stock merger to bolster its cash reserves by approximately $33 million.

In 2009, OXiGENE re-acquired full rights to its lead candidates, ZYBRESTAT and OXi4503, from Symphony ViDA. Lead Pharmaceutical Pipeline Oxigene

OXiGENE, Inc. was a clinical-stage biopharmaceutical company that rebranded as in June 2016. The company specialized in developing Vascular Disrupting Agents (VDAs) designed to selectively dismantle blood vessels that sustain solid tumors and contribute to visual impairment. Corporate Evolution In 2010, OXiGENE acquired VaxGen, Inc

OXiGENE’s primary development programs were based on , natural products originally derived from the African bush willow tree. Drug Candidate Indication Current Status/Highlights CA4P (Fosbretabulin) Ovarian Cancer, Glioblastoma, Anaplastic Thyroid Cancer OXiGENE acquired VaxGen